These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Eukaryotic expression and tumor-targeting modification of human mutated-IL-18 fusion gene].
    Author: Lü JX, Peng Y, Meng ZF.
    Journal: Yi Chuan; 2005 Jul; 27(4):557-60. PubMed ID: 16120577.
    Abstract:
    Interleukin-18 (IL-18) is a proinflammatory cytokinin. This protein has a role in regulating immune responses and exhibits significant anti- tumor activities. Epidermal growth factor (EGF) is an important growth factor that plays a central role in the regulation of cell cycle and differentiation. It was proposed that a targeted delivery of IL-18 by generation of IL-18-EGF fusion protein might decrease adverse effects and result in enhancing cytotoxic and antitumor activities. In the present study, a fusion protein, consisting of EGFR binding domain fused to human IL18 mature peptide via a linker peptide of (Gly4ser) 3, was constructed and expressed in the insect cell line Sf9 using Bac-to-Bac baculovirus expression system. We showed that the purified recombinant fusion protein induced similar levels of IFN-gamma to that of native IL-18 protein in human PBMC in the presence of ConA. Furthermore, EGF Receptor competitive test in human epithelial cancer A431 cell line showed that EGF- IL18 fusion protein can specifically bind with EGFR by competing with native EGF protein. The results suggested that EGF-IL18 fusion protein could specifically be targeted on tumor cells. The work may provide a new insight into the cytokinin for the tumor treatment.
    [Abstract] [Full Text] [Related] [New Search]